1. HUNT R.H. Eradication of Helicobacter pylori infection. Am J Med 1996; 100 (suppl 5A): 42S-51S.

2. BARDHAN P.K. Epidemiological features of Helicobacter pylori infection in developing countries. Clínical Infectious Diseases 1997; 25: 973-978.

3. CAVE D.R. Transmission and epidemiology of Helicobacter pylori. Am J Med 1996; 100 (suppl 5A): 12S-19S.

4. KLEIN P.D. Gastrointestinal Physiology Working Group, Graham D.Y., Gaillour A., Opekun A.R., O'Brian Smith E. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Lancet 1991; 337: 1503-1506.

5. RECAVARREN S., LEÓN-BARÚA R., COK J., et al. Helicobacter pylori and progresssive pathology that predisposes to gastric cancer. Scandinavian Journal of Gastroenterology 1991; 26 (suppl 181): 51-57.

6. THOMAS J.E., GIBSON G.R., DARBOE M.K., et al. lsolation of Helicobacter pylori from human faeces. Lancet 1992; 340: 1194-1195.

7. LEÓN-BARÚA R., RECAVARREN S., BERENDSON R., GILMAN R.H. Helycobacter pylori y cáncer gástrico. Rev Gastroent Perú 1995; 15 (suppl 1): S23-S27.

8. TYTGAT G.N.J., NOACH L.A., RAUWS E.A.J. Helicobacter pylori infection and duodenal ulcer disease. Gastroenterol Clin North Am 1993; 22: 127-138.

9. RAUWS E.A.J., VAN DER HULST R.W.M. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs 1995; 50 (6): 984-990.

10. FORBES G.M., GLASER M.E., CULLEN D.J., et al. Duodenal ulcer treatment with Helicobacter pylori eradication: seven year follow up. Lancet 1994; 343: 258-260.

11. SOLL A., Consensus statement. Medical treatment of peptic ulcer disease. JAMA 1996; 275: 622-629.

12. N.I.H., Consensus conference. Heficobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-69.

13. LEÓN-BARÚA R., BERENDSON R., RECAVARREN S., GILMAN R.H. Geographic factors probably modulating alternative pathways in Helicobacter pylori-associated gastroduodenal pathology a hypothesis. Clinical Infectious Diseases 1997; 25: 1013-1016.

14. RECAVARREN S., GILMAN R,H., LEÓN-BARÚA R., et al. Chronic atrophic gastritis: early diagnosis in a population where Helicobacter pylori infection is frecuent. Clinical Infectious Diseases 1997; 25: 1006-1012.

15. LEÓN-BARÚA R., RECAVARREN S., RAMÍREZ-RAMOS A. El aporte peruano a la investigación sobre Helicobacter pylori. Rev Med Herediana 1991; 2 (4): 173-181.

16. CONTARDO C. Rol de Helicobacter pylori en la patología tumoral gastroduodenal. Rev Gastroent Perú 1995; 15 (suppl 1): S13-S20.

17. GOODWIN C.S. Helicobacter pylori gastritis, peptic ulcer and gastric cancer: clinical and molecular aspects. Clínical Infectious Diseases 1997; 25: 1017-1019.

18. HOWDEN C.W. Clinical expressions of Helicobacter pylori infection. Am J Med 1996; 100 (suppl 5A): 27S-34S.

19. LEÓN-BARÚA R., RECAVARREN S., GILMAN R.H.,BERENDSON R. Can eradication of Helicobacter pylori prevent gastric cancer? Drugs 1993; 46 (3): 341-346.

20. LANZA F.L. Tumors of the stomach. En Conn's Current Therapy. Rakel Ed. 50 th edition. 1998 W.B. Saunders Company. Philadelphia, Pennsylvania. pp. 529.

21. WOTHERSPOON A.C., DOGLIONI C., DISS T.C., et al. Regression of low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577.

22. RAMÍREZ-RAMOS A. Tratamiento de la infección por Helicobacter pylori: estado actual. Rev Gastroent Perú 1995; 115 (suppl 1): S7-S21.

23. HUNT R. The management of acid-related disorders: clinical practice and therapeutics principles. Am J Gastroenterol 1997; 92 (4): 36-43.

24. GLUPCZYNSKI Y., BURETTE A., DE KOSTER A., et al. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976-977.

25. VÁSQUEZ A., VALDEZ Y., GILMAN R.H., et al. Metronidazole and clarithomycin resistance in Helicobacter pylori determined by measuring MlCs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. J Clin Microbiol 1996; 34: 1232-1234.

26. BERG D.E., GILMAN R.H., JANAKI L.G., et al. Helicobacter pylori populations in Peruvian patients. Clinical Infectious Diseases 1997; 25: 996-1002.

27. GOODWIN C.S. Antimicrobial treatment of Helicobacter pylori infection. Clinical Infectious Diseases 1997; 25: 1023-1026.

28. HOSKING S.W., LING T.K.W., CHUNG S., et al. Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial. Lancet 1994; 343: 508-10.

29. ZHENG Z.T., WANG Y.B. Treatment of peptic ulcer with furazolidone. J Gastroenterol Hepatol 1992; 7 (5): 533-537.

30. ZHENG Z.T., WANG Z.Y., CHU Y.X., et al. Doubleblind short-term trial of furazolidone in peptic ulcer. Lancet 1985; 325: 1048-1049.

31. COELHO L.G., PASSOS M. DO C., QUEIROZ D.M., et al. Furazolidone and cimetidine in patients with active duodenal ulcer and Helicobacter pylori in the gastric antrum. Arq Gastroenterol 1991; 28 (1): 9-15.

32. COEHLO L.G., PASSOS M. DO C., CHAUSSON Y., CASTRO L. DE P. Five-day bismuth-free triple therapy for eradication of Helicobacter pylori and reduction of duodenal ulcer relapse. Am J Gastroenterol 1991; 86 (8): 971-975.

33. ZATERKA S., EISIG J.N., CHINZON D., et al. Five-day and ten-day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer. Rev Hosp Clin Fac Med Sau Paulo 1996; 51 (5): 162-165.

34. GUTIÉRREZ O., RICAURTE O., CAMARGO H., et al. Bismuth and furazolidone vs. sucralfate in the treatment of patients with non ulcer dyspepsia (NUD) associated to Helicobacter pylori. Gastroenterology 1994;106 (4) (suppl 2): A86.

35. GUTIÉRREZ O., RICAURTE O., CORREA P., et al. Bismuth and furazolidone vs. ranitidine in non ulcer dyspepsia (NUD) associated to Helicobacter pylori. Gastroenterology 1994; 106 (4) (suppl 2): A86.

36. SEGURA, A.M., GUTIERREZ 0., OTERO W., et al. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11 (3): 529-532.

37. LIU W., XIAO S., SHI Y., et al. Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1999; 13 (3): 317-322.

38. XIAO S., LIU W., HU P., et al. High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week. Aliment Pharmacol Ther 1999; 13 (3): 311-315.

39. VAN ZWEET A., THIJS J.C., VAN DER WOUDEN E.J., KOOY A. Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week. Aliment Pharmacol Ther 1997; 11 (3): 533-535.

40. XIAO S., LIU W., XIA D., et al. The efficacy of furazolidone and metronidazole in the tratment of chronic gastritis associated with Helicobacter pylori. Hepatogastroenterology 1990; 37 (5): 503-506.

41. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universisties. Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. Gastroenterology 1988; 95: 1178-84.

42. RAMÍREZ-RAMOS A., GILMAN R.H., LEÓN-BARÚA R., RECAVARREN S.,WATANABE J., for the Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University, et al. Rapid recurrence of Helicobacter pylori infection in peruvian patients after successful eradication. Clinical Infectious Disease 1997; 25: 1027-1031.

43. PÁUCAR H., ARRUNÁTEGUI L., CABELLO J., et al. Tratamiento de la úlcera péptica duodenal mediante erradicación del H. pylori: estudio controlado randomizado. Rev Gastroent Perú 1997; 17: 203-213.

44. ROBERT M., WEINSTEIN W. Helicobacter pylori-associated gastric pathology. Gastroenterol Clin North Am 1993; 22: 59-71.

45. CUTLER A.F. Testing for Helicobacter pylori in clinical practice. Am J Med 1996; 100 (suppl 5A): 35S-41 S.

46. MISIEWICZ J.J., TYTGAT G.N.J., GOODWIN C.S., et al. The Sidney System: a new classification of gastritis. Working Party Report of the 4th World Congress of Gastroenterology, Sidney 1990: 1-10.

47. MAGHIDMAN, S. "Gastritis nodular": experiencia en el Hospital Nacional Cayetano Heredia. Tesis para optar el grado de Bachiller en Medicina. UPCH. 1999.

48. PEURA D.A. Helicobacter pylori and ulcerogenesis. Am J Med 1996; 100 (suppl 5A): 19S-26S.

49. GURBUZ A.K. GIARDIELLO F.M., DAGALP K., et al., Clarithromycin and omeprazole for Helicobacter pylori gastritis: an unsatisfactory regimen. Gastroenterology 1994; 1O6 (4), parte 2: A86.

50. Vademécum Médico del Perú de "La Revista Médica". 1era. edición. Editado por Pablo Grimberg-CEIC. Lima, Perú 1998. pp. 714.

51.   CUTLER A.F., SCHUBERT T. Long-term Helicobacter pylori recurrence after successful eradication with triple therapy. Am J Med 1993; 88 (9): 1359-1361.